You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

NA

Introducing OMJJARA▼ (momelotinib)

A treatment option for splenomegaly or symptoms in patients who have myelofibrosis and moderate to severe anaemia.

Date of Preparation: September 2024 PM-IE-MML-WCNT-240001

▼ This medicinal product is subject to additional monitoring.

Prescribing information link

Quick links

Therapy Area

Oncology

Respiratory

Vaccines

HIV

See all therapy areas

Resources:

Patient resources

Sample and training devices

Healthcare professional resources

See all resources

Live and On-Demand Events:

View sessions with healthcare experts in Oncology, Respiratory and Vaccines at live and on-demand events.

See all events

Respiratory

Arexvy▼ (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

learn more

Respiratory

Shingrix (herpes zoster vaccine recombinant, adjuvanted)

learn more

Respiratory

Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol [as trifenatate])

learn more

Respiratory

Zejula (Niraparib)

learn more

HIV

HIV

Access the latest news, clinical data & resources about our portfolio of antiretroviral medicines.

learn more

Oncology

Oncology

Information about our oncology portfolio as well as resources and latest news

learn more

Respiratory

Respiratory

Information about our respiratory portfolio, as well as resources and latest news.

learn more

Vaccines

Vaccines

Information about our vaccine portfolio, as well as resources and latest news.

learn more

More Information

Oncology

Dovato (dolutegravir/lamivudine)

Virological suppression is the first step to achieving HIV+Healthy. For your patients living with HIV, learn more about how Dovato could be a part of their healthy future.1

Learn More

Prescribing information

Outstretched hand preventing visual representation of disease.

Arexvy▼ (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted))

AREXVY is indicated for the active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older.2

Learn More

Prescribing information

Zejula▼ (Niraparib)

Zejula (Niraparib) patient booklet available to order online

This Zejula patient booklet has been developed to provide information on some of the questions patients prescribed Zejula may have and helps to support them on their treatment journey.3

Order today

Prescribing information

cheerful man over 60s kayaking

If you can prevent Shingles suffering, why wouldn't you?4

Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in adults 50 years of age or older and in adults 18 years of age or older at increased risk of HZ.4

Learn more

Prescribing information

Get more from GSKpro

Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines

Register in 2 Minutes

References

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  2. Arexvy, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/arexvy-powder-and-suspension-for-suspension-for-injection-35441/spc. Last Accessed: September 2024
  3. Zejula, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/zejula-100-mg-hard-capsules-35060/spc Last Accessed: September 2024
  4. Shingrix, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc Last Accessed: September 2024

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-NA-WCNT-220010 Date of Preparation: September 2024